Paxman
Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45
Xbrane clears the FDA, BioInvent seeks 430 Mkr and Genmab keeps surging – the Nordic Pulse | 2026:44
Analytics
Egetis wins FDA approval, Indices retreat across the board – the Nordic Pulse | 2026:40
AstraZeneca fires three barrels, Implantica enters the US – the Nordic Pulse | 2026:34
Demant raises the bar, XVIVO clears hearts and Zealand cashes in – the Nordic Pulse | 2026:33
Paxman får CPT-koder för neuropatibehandling i USA
Paxman meddelar om Medicare-ersättningar för 2026
Paxman presenterar lovande CIPN-data vid ESMO-kongressen
Paxman godkänd för FDA:s STeP-program
PAXMANs grundare minskar sitt aktieinnehav
Nyhetssvepet måndag 2 juni
